CymaBay stock: buy or sell?

CBAY stock price: $5.63 1.08% At close on September 20th, 2019

Updated on:
September 20th, 2019

0

CymaBay Therapeutics appreciated a beatiful 1.08% and closed at $5.63.

Cymabay Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases.

Should I buy CymaBay stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with CymaBay Therapeutics stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean CBAY will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is CymaBay stock a buy?

Banks and financial institutions publish stock ratings everyday. At Stocks2.com, we gathered 9 ratings published for CBAY stock in the last 30 days.

The general sentiment of these ratings is bullish for CBAY stock, with 7 positive ratings.
Is CBAY a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-14Evercore ISIn/aBuy
2019-6-17B. Rileyn/aHold
2019-6-13Citigroupn/aBuy
2019-6-12HC Wainwrightn/aBuy
2019-6-11Piper Jaffray CompaniesOverweightMarket Perform
2019-5-14Citigroupn/aBuy
2019-4-23Raymond Jamesn/aBuy
2019-2-22Leerink Swannn/aOutperform
2019-2-1Cantor Fitzgeraldn/aBuy

CymaBay stock analysis

Daily outlook

CymaBay Therapeutics appreciated a beatiful 1.08% and closed at $5.63.

Shares of CymaBay closed yesterday at $5.63 and appreciated a beatiful 1.08%. Since June when CBAY stock price broke down the SMA200d line, it slid $-5.46 per share (-49.23%).

CBAY stock chart (daily)

Weekly outlook

Shares of CymaBay slightly fell a rough -2.09% this week. Late August CBAY climbed a super good 6.59% in just one week. By mid August CBAY plunged a horrible -5.24% in just one week.

CymaBay stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Since price and 40-weeks moving average lines crossed down by mid June, CBAY fell $-5.88 per share (-51.09%). Stocks below the 40w moving average line are usually not recommended for average traders.

CBAY stock chart (weekly)

CymaBay stock price history

CymaBay stock went public on February 3rd, 2014 with a price of $5.001. Since then, CBAY stock grew a 12.60%, with an average of 2.50% per year. If you had invested $1,000 in CymaBay stock in 2014, it would worth $126.00 today.

1: Adjusted price after possible price splits or reverse-splits.

CymaBay stock historical price chart

CBAY stock reached 52-week highs on March at $14.00, and all-time highs 2018-03-05 with a price of 15.59.

CymaBay stock price target is $14.10

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' CBAY stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we found 8 price predictions for CymaBay stock:
CBAY stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-14Evercore ISIReiteratesn/a$15.00-
2019-6-17B. RileySet Price Targetn/a$7.00-
2019-6-13CitigroupLowers Target$21.00$12.00-42.9%
2019-6-12HC WainwrightReiterates$24.00$12.00-50%
2019-6-11Piper Jaffray CompaniesLowers Target$30.00$8.00-73.3%
2019-5-14CitigroupInitiatesn/a$21.00-
2019-4-23Raymond JamesSet Price Targetn/a$18.00-
2019-2-1Cantor FitzgeraldReiteratesn/a$20.00-
(in average)$25.00$14.10-44.0%
Moving in a range from $21.00 and $7.00, the price target for CBAY stock is $14.10. In average, analysts' outlook on CBAY price target is negative, downgrading the forecast by a -44.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, CymaBay Therapeutics didn't meet the expectations of the experts and posted a fateful EPS of $-0.32 per share when experts were expecting $-0.36.
CBAY earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.2n/a
2017-Q2-n/a-0.31n/a
2017-Q32017-11-08-0.19-0.21n/a
2017-Q42018-03-15-0.17-0.11n/a
2018-Q12018-05-08-0.14-0.32n/a
2018-Q22018-08-09-0.25-0.3n/a
2018-Q32018-11-06-0.3-0.34n/a
2018-Q42019-02-28-0.36-0.32n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

Compared to , last anual revenues report draw of to $10.00 M dollars. When comparing 2017 vs , , profit margin (that is, the net income divided by revenues) a to -275.57%.

CBAY annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2017$10 M-$-27.56 M-275.6%-

Quarterly financial results

Reported quarter earnings marked $-19.45 million with a profit margin of . Profit margin stayed constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, CymaBay Therapeutics sales marked a spooky decrease and plummed a -100.00%. Looking back to recent quarterly results, CymaBay Therapeutics posted 4 negative quarters in a row.
CBAY quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$4.79 M-$-5.35 M-111.7%-
2017-Q4$5.21 M8.71%$-5.04 M-96.9%-5.74%

CymaBay ownership

When you are planning to invest in a stock, it's worth to check its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For CymaBay, 0.74% of all outstanding shares are owned by its staff.

Bearish positions for CBAY stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to CymaBay Therapeutics:

CBAYBMYPFEPTCTXNCR
Market cap$386.8 M$82.9 B$202.9 B$1.8 B$2.1 B
Total shares68.7 M1,640.0 M5,530.0 M46.4 M56.6 M
Float shares50.6 M1,630.0 M5,490.0 M54.2 M56.1 M
  - Institutional holdings (%)88.5%75.0%76.2%85.6%85.8%
  - Insider holdings (%)0.7%0.1%0.0%2.7%13.4%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

CymaBay summary

Friday, September 20th, 2019
Open$5.55
Close$5.63
Day range$5.43 - $5.65
Previous close$5.57
Session gain1.08%
Average true range$0.30
50d mov avg$5.99
100d mov avg$7.98
200d mov avg$9.30
Daily patternlt06c
Weekly pattern lt06a

CymaBay performance

To better understand CymaBay performance you must becnhmark its gains with other related stocks in same sector or industry. For CymaBay Therapeutics, the benchmark is made against Bristol-Myers Squibb, Pfizer, PTC Therapeutics and Xencor.
Stock3m6m12m
CBAYCymaBay Therapeut...-20.37%-52.81%-50.57%
BMYBristol-Myers Squ...3.39%6.87%-16.14%
PFEPfizer-15.21%-10.73%-13.79%
PTCTPTC Therapeutics-10.72%3.34%-13.67%
XNCRXencor4.98%23.28%-13.94%

CymaBay competitors

We chose a few stocks to conform a list of CymaBay Therapeutics competitors to check if you are interested in investing in CBAY: